Page 37 - GB-RI-PierreFabre-Complet-INTERACTIF

Oncology revenues up by more than Caring for cancer A pioneer in oncology for nearly four decades, Pierre Fabre makes cancer treatment and prevention a research and development priority. The Group invests in and works on cancer prevention through its offer of sunscreens and by carrying out information and training initiatives for the detection of certain types of cancer. The Groups develops and sells innovative treatments for cancers such as breast, lung, colorectal, and skin cancer. These innovations are the result of our in-house research and co-development partnerships (with Pfizer and Puma Biotechnology in particular). +35 % vs. 2019 Nearly 90% of revenue generated internationally On average, around 1,500 patients with BRAF+ melanoma received a Pierre Fabre treatment in 2020 A major therapeutic breakthrough for relapsed breast cancer Although one in eight women will develop breast cancer in their lifetime, only 20% of those will be affected by an HER2+ mutation in particularly aggressive tumors. The risk of post-treatment relapse therefore affects one in four patients. Neratinib is a molecule that offers an effective treatment response for patients with this form of cancer. Used as extended adjuvant treatment, the molecule reduces the 2-year relapse rate by 51%. Thanks to a marketing agreement with Puma Biotechnology, Pierre Fabre has been manufacturing and selling this adjuvant treatment since 2019. The exclusive agreement covers Europe, the Middle East, Turkey, part of Africa, and was extended to China in 2021. BUSINESS MODEL 33